Since VEGF is highly elevated in advanced ROP and has been found to play a central role as the driving force for neovascularization [118,119,120], the blocking of VEGF by anti-VEGF agents is a logical approach. The gene discussed is VEGFA; the disease is retinopathy of prematurity.